This study is testing a drug called CBL0137 for children and young adults with certain cancers that have come back or don't respond to treatment. CBL0137 works by blocking signals in cells that help cancer grow.

Key Points:

• This study involves getting CBL0137 through an IV on specific days, repeating every 21 days for up to 17 cycles, unless there are problems.
• Participants will have regular check-ups and tests, including blood tests and heart checks, during the study and for a while after.
• The study is for children and young adults aged 12 months to 30 years, depending on their specific type of cancer.

Participants must have tried other treatments that didn't work, and must be able to handle the study's procedures. They should not be pregnant or be taking certain other medications. After the treatment, participants will be followed for up to five years to monitor their health. This study helps find the best dose and understand the side effects and benefits of CBL0137 in treating these cancers.